JP5022216B2 - 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法 - Google Patents

自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法 Download PDF

Info

Publication number
JP5022216B2
JP5022216B2 JP2007515646A JP2007515646A JP5022216B2 JP 5022216 B2 JP5022216 B2 JP 5022216B2 JP 2007515646 A JP2007515646 A JP 2007515646A JP 2007515646 A JP2007515646 A JP 2007515646A JP 5022216 B2 JP5022216 B2 JP 5022216B2
Authority
JP
Japan
Prior art keywords
antagonist
syndrome
disease
onset
nomid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007515646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501716A5 (enExample
JP2008501716A (ja
Inventor
スコット メリス，
マーガレット カロー，
ジョージ ディー． ヤンコプロス，
ジョアンヌ パパドプロス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2008501716A publication Critical patent/JP2008501716A/ja
Publication of JP2008501716A5 publication Critical patent/JP2008501716A5/ja
Application granted granted Critical
Publication of JP5022216B2 publication Critical patent/JP5022216B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2007515646A 2004-06-04 2005-06-03 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法 Expired - Fee Related JP5022216B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57702304P 2004-06-04 2004-06-04
US60/577,023 2004-06-04
PCT/US2005/019674 WO2005117945A1 (en) 2004-06-04 2005-06-03 Methods of using il-1 antagonists to treat autoinflammatory disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012012800A Division JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Publications (3)

Publication Number Publication Date
JP2008501716A JP2008501716A (ja) 2008-01-24
JP2008501716A5 JP2008501716A5 (enExample) 2008-04-24
JP5022216B2 true JP5022216B2 (ja) 2012-09-12

Family

ID=34972252

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007515646A Expired - Fee Related JP5022216B2 (ja) 2004-06-04 2005-06-03 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法
JP2012012800A Pending JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012012800A Pending JP2012111768A (ja) 2004-06-04 2012-01-25 自己炎症性疾患を処置するためのｉｌ−１アンタゴニストを使用する方法

Country Status (9)

Country Link
US (4) US7459426B2 (enExample)
EP (1) EP1750746A1 (enExample)
JP (2) JP5022216B2 (enExample)
CN (1) CN1964737B (enExample)
AU (1) AU2005249570B2 (enExample)
CA (1) CA2568352C (enExample)
IL (1) IL179512A0 (enExample)
MX (2) MXPA06014126A (enExample)
WO (1) WO2005117945A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005249503B2 (en) * 2003-11-10 2011-08-25 Vertex Pharmaceuticals Incorporated ICE inhibitors for the treatment of autoinflammatory diseases
AU2005216298B2 (en) 2004-02-26 2010-09-02 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
US20060160737A1 (en) * 2005-01-14 2006-07-20 Allen Radin Methods of using IL-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis
EP2848258B1 (en) * 2005-10-26 2017-12-13 Novartis AG Treatment of familial Mediterranean Fever with anti IL-1beta antibodies
CN101378764A (zh) * 2005-12-09 2009-03-04 贝勒研究院 通过血液白细胞微阵列分析对系统性红斑狼疮的诊断、预后和疾病发展的监测
MX2009004051A (es) * 2006-10-20 2009-05-11 Regeneron Pharma Uso de antagonistas de il-1 para tratar gota y pseudo gota.
US7632490B2 (en) 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
JP5272735B2 (ja) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 生物学的製剤
WO2008112772A2 (en) * 2007-03-14 2008-09-18 Baylor Research Institute Gene expression in peripheral blood mononuclear cells from children with diabetes
EP3406263A1 (en) * 2007-05-29 2018-11-28 Novartis AG New indications for anti-il-1beta therapy
KR20120082906A (ko) 2009-09-30 2012-07-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
ES2703774T3 (es) 2010-06-18 2019-03-12 Xbiotech Inc Tratamiento para la artritis
SG187231A1 (en) 2010-07-29 2013-02-28 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
JP6431476B2 (ja) * 2012-03-31 2018-11-28 アール−ファーム・インターナショナル・リミテッド・ライアビリティ・カンパニーＲ−Ｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｌｌｃ オステオプロテゲリン由来の組成物およびその使用
CN103509100B (zh) * 2012-06-15 2017-10-27 上海百迈博制药有限公司 一种白细胞介素‑1受体拮抗剂突变体
WO2014035361A1 (en) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) IL-1β INHIBITOR COMPOSITION AND USE THEREOF
CN107693781B (zh) 2013-03-13 2021-11-09 巴扎德制药公司 用于眼部递送的嵌合细胞因子制剂
AU2014274044B2 (en) * 2013-05-31 2019-06-27 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat Alzheimer's Disease
AU2014308751B2 (en) * 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
WO2015147789A1 (en) * 2014-03-24 2015-10-01 R-Pharm Overseas, Inc. Human il 1-r1 derived inhibitor of il-1b
JP6565099B2 (ja) * 2015-09-18 2019-08-28 国立大学法人 長崎大学 家族性地中海熱のバイオマーカー
BR112018006578A2 (pt) * 2015-10-01 2018-12-26 Heat Biologics, Inc. composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas
WO2017152254A1 (en) * 2016-03-09 2017-09-14 Chu Sainte-Justine Methods for reducing perinatal morbidity and/or mortality
EP3582813A4 (en) * 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
AU2018249816B2 (en) * 2017-04-03 2025-04-17 Wisconsin Alumni Research Foundation Mineral coated microparticles for sustained delivery of biologically active molecules
EP3908613A4 (en) * 2019-01-07 2022-10-19 Celluris Participações Ltda. BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA
EP4054564A1 (en) * 2019-11-07 2022-09-14 Inflazome Limited Treatment of autoinflammatory disorders
JP7072260B2 (ja) * 2019-12-27 2022-05-20 国立大学法人愛媛大学 マックル・ウェルズ症候群の治療用医薬組成物
WO2021184128A1 (en) * 2020-03-20 2021-09-23 Institut De Cardiologie De Montreal Methods of treating a coronavirus infection using colchicine
KR20220158821A (ko) * 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
TW202210068A (zh) * 2020-06-05 2022-03-16 美商雅力思提雅治療公司 用於治療家族性地中海型發熱病的cxcr-2抑制劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
EP2241328A1 (en) * 2000-05-12 2010-10-20 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
CN104178491B (zh) 2002-09-06 2018-07-03 安姆根有限公司 治疗性人抗-il-1r1单克隆抗体
US20050129685A1 (en) * 2003-09-18 2005-06-16 Jingtai Cao Use of IL-1 blockers to prevent corneal inflammation and neovascularization

Also Published As

Publication number Publication date
CA2568352A1 (en) 2005-12-15
US20090156492A1 (en) 2009-06-18
CN1964737B (zh) 2011-04-20
MXPA06014126A (es) 2007-07-18
CN1964737A (zh) 2007-05-16
EP1750746A1 (en) 2007-02-14
JP2012111768A (ja) 2012-06-14
US8414876B2 (en) 2013-04-09
US20050272655A1 (en) 2005-12-08
US20110311537A1 (en) 2011-12-22
AU2005249570B2 (en) 2011-06-16
AU2005249570A1 (en) 2005-12-15
US7459426B2 (en) 2008-12-02
IL179512A0 (en) 2007-05-15
HK1100837A1 (en) 2007-09-28
MX344967B (es) 2017-01-12
WO2005117945A1 (en) 2005-12-15
CA2568352C (en) 2011-09-13
JP2008501716A (ja) 2008-01-24
US20110318342A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
US8414876B2 (en) Methods of using IL-1 antagonists to treat autoinflammatory disease
EP1071449B1 (en) Use of an antagonist antibody to the inflammatory mediator oncostatin m (osm)
Goldenberg Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis
JP5397948B2 (ja) 痛風および偽痛風を治療するための、ｉｌ−１アンタゴニストの使用
US20090226426A1 (en) Method for treating inflammation
JP2005525404A (ja) Ｈｉｖ感染およびａｉｄｓを処置するためにサイトカインアンタゴニストを使用する方法
JP2008538553A (ja) Ｉｌ−２１／ｉｌ−２１ｒアンタゴニストによって線維症を治療および予防する方法
US20060171948A1 (en) Methods of using IL-1 antagonists to reduce C-reactive protein
Zhang et al. A novel single domain bispecific antibody targeting VEGF and TNF-α ameliorates rheumatoid arthritis
CN122029185A (zh) 包含TNF同源结构域和突变的Fc结构域的TNF受体2特异性激动剂融合蛋白
CN108295242A (zh) 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用
US12043672B2 (en) Compositions comprising bispecific antibodies to human ADAMTS5 and nerve growth factor
AU2011224099B2 (en) Methods of using IL-1 antagonists to treat autoinflammatory disease
WO2006084145A2 (en) Methods of using il-1 antagonists to reduce c-reactive protein
Towns et al. Inhibition of Interleukin-1 as a Strategy for the Treatment of Rheumatoid Arthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110315

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120319

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120406

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120531

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120615

R150 Certificate of patent or registration of utility model

Ref document number: 5022216

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150622

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees